Peter Feinberg Purchases 20,000 Shares of Immuneering (NASDAQ:IMRX) Stock

Immuneering Corporation (NASDAQ:IMRX) Director Peter Feinberg purchased 20,000 shares of the firm’s stock in a transaction dated Monday, January 12th. The shares were bought at an average cost of $4.35 per share, with a total value of $87,000.00. Following the purchase, the director directly owned 135,441 shares of the company’s stock, valued at approximately $589,168.35. This represents a 17.32% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Immuneering Trading Down 1.9%

IMRX opened at $4.14 on Wednesday. The company has a market capitalization of $267.32 million, a price-to-earnings ratio of -2.33 and a beta of 0.48. Immuneering Corporation has a 12-month low of $1.10 and a 12-month high of $10.08. The business’s fifty day simple moving average is $6.49 and its 200-day simple moving average is $5.79.

Immuneering (NASDAQ:IMRX) last posted its earnings results on Wednesday, November 12th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). On average, equities research analysts predict that Immuneering Corporation will post -1.86 EPS for the current year.

Institutional Investors Weigh In On Immuneering

A number of large investors have recently made changes to their positions in the stock. Jane Street Group LLC purchased a new position in Immuneering in the 1st quarter worth $32,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Immuneering in the third quarter worth about $35,000. Future Financial Wealth Managment LLC acquired a new stake in shares of Immuneering during the third quarter worth about $35,000. Kingsview Wealth Management LLC acquired a new stake in shares of Immuneering during the second quarter worth about $47,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in Immuneering in the third quarter valued at approximately $70,000. 67.65% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IMRX has been the topic of several analyst reports. Oppenheimer lifted their target price on Immuneering from $21.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, September 25th. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Immuneering in a research note on Tuesday, September 30th. Wall Street Zen downgraded Immuneering from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research report on Monday, December 29th. Finally, Leerink Partners began coverage on Immuneering in a research note on Friday, October 31st. They set an “outperform” rating and a $15.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $16.50.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.